Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13163312 | 0.90 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL21820652 | 0.84 | WDR5 (0.38) | MEN1KMT2ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL8179858 | 0.83 | HDAC4 (0.40) | KMT2AOPRM1LMNA | |
| SCHEMBL8097373 | 0.82 | OPRM1 (0.45) | MEN1KMT2ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL11866905 | 0.79 | KMT2A (0.57) | KMT2AALDH1A1LMNA | |
| SCHEMBL735798 | 0.79 | MEN1 (0.57) | MEN1KMT2ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL56575 | 0.78 | NPC1 (0.57) | MEN1KMT2ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL872608 | 0.78 | OPRM1 (0.56) | MEN1KMT2ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL19772418 | 0.77 | SLC6A4 (0.52) | OPRM1OPRL1 | |
| SCHEMBL3521450 | 0.77 | SLC6A4 (0.52) | OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357704-B2 | Fused heterocyclic compounds as inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357704-B2 | Fused heterocyclic compounds as inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-20100247534-A1 | FUSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-20100247534-A1 | FUSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-7772232-B2 | Quinazolinyl compounds as inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772232-B2 | Quinazolinyl compounds as inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7276631-B2 | Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7098203-B2 | Homopiperidine derivatives as NK-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-29 | — | — | US | disclosed |
| WO-2006014703-A2 | HOMOPIPERDININE DERIVATIVES AS NK-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006014664-A2 | CYCLOPENTYLAMINE AND CYCLOHEXYLAMINE DERIVATIVES AS NK-1/SSRI ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060019943-A1 | Homopiperidine derivatives as NK-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-26 | — | — | US | disclosed |
| US-20060019944-A1 | Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019943-A1 | Homopiperidine derivatives as NK-1 antagonists | HTR1D, HTR5A, SLC6A4 | MEN1 1668/4885KMT2A 774/4885SMN1; SMN2 3503/4885 |
| US-20100247534-A1 | FUSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNH2, KCNH3, KCNB1 | MEN1 544/4885KMT2A 641/4885SMN1; SMN2 2059/4885 |
| US-20060019944-A1 | Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists | SLC6A4, SLC6A2, SLC6A1 | MEN1 3386/4885KMT2A 932/4885SMN1; SMN2 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.